PureTech Health

AI Score

XX

Unlock

19.00
-0.10 (-0.52%)
At close: Apr 02, 2025, 3:58 PM
19.05
0.26%
After-hours: Apr 02, 2025, 04:00 PM EDT
-0.52%
Bid 18
Market Cap 456.36M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -3
PE Ratio (ttm) -6.33
Forward PE -3.74
Analyst Buy
Ask 20
Volume 9,577
Avg. Volume (20D) 2,475
Open 18.64
Previous Close 19.10
Day's Range 18.50 - 19.10
52-Week Range 16.30 - 34.00
Beta 0.98

About PRTC

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platfo...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 16, 2020
Employees 90
Stock Exchange NASDAQ
Ticker Symbol PRTC
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for PRTC stock is "Buy." The 12-month stock price forecast is $45, which is an increase of 136.84% from the latest price.

Stock Forecasts
3 months ago
+8.85%
PureTech Health shares are trading higher after th... Unlock content with Pro Subscription
7 months ago
-6%
PureTech Health shares are trading lower after the company reported a year-over-year decrease in H1 financial results.